News & Events

Adagrasib (Krazati; MRTX849): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in KRAS G12C-Mutated Cancers

Adagrasib (Krazati; MRTX849): Understanding Its Mechanism, Dosing, Clinical Uses, and Role in KRAS G12C-Mutated Cancers

Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

‘Major improvement’: Divarasib extends survival in KRAS G12C-mutated NSCLC

‘Major improvement’: Divarasib extends survival in KRAS G12C-mutated NSCLC

Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC

Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C-Mutated NSCLC

ESMO: PFS, OS Extended With Divarasib in KRAS G12C-Mutated Advanced NSCLC

ESMO: PFS, OS Extended With Divarasib in KRAS G12C-Mutated Advanced NSCLC

Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Divarasib as Compared with Sotorasib or Adagrasib in KRAS G12C–Mutated NSCLC

Divarasib in Previously Treated Advanced KRAS G12C–Mutated NSCLC

Divarasib in Previously Treated Advanced KRAS G12C–Mutated NSCLC

Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer

Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer

Divarasib improves survival in previously treated KRAS G12C mutated advanced NSCLC

Divarasib improves survival in previously treated KRAS G12C mutated advanced NSCLC

ESMO Congress 2026: Next-generation KRAS inhibitor outperforms rivals in lung cancer

ESMO Congress 2026: Next-generation KRAS inhibitor outperforms rivals in lung cancer